Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that on December 6, 2019 it closed the previously announced underwritten public offering of 4,600,000 shares of its common stock, which included shares issued upon the exercise in full by the underwriters of their option to purchase 600,000 additional shares. The offering was priced at $58.00 per share, and the company received gross proceeds of $266.8 million, before deducting underwriting discounts, commissions and other offering expenses payable by the company.

Arrowhead Pharmaceuticals Closes Underwritten Public Offering with Gross Proceeds of $266.8 Million

Pasadena, CA | Posted on December 7th, 2019

Goldman Sachs & Co. LLC, Jefferies LLC and Piper Jaffray & Co. are acting as bookrunning managers for the offering, Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering and Robert W. Baird & Co. Incorporated and B. Riley FBR, Inc. are acting as co-managers for the offering. Arrowhead intends to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures and clinical trial expenditures. A portion of the net proceeds may also be used for the acquisition of complementary businesses, products and technologies, or for other strategic purposes.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

####

About Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference, or RNAi, mechanism to induce rapid, deep, and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding our expectations with respect to the use of proceeds from Arrowhead’s public offering. These statements are based upon our current expectations and speak only as of the date hereof. Arrowhead’s actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including, without limitation, risks and uncertainties associated with market conditions. Arrowhead’s most recent Annual Report on Form 10-K and other filings Arrowhead makes with the SEC from time to time discuss some of the important risk factors that may affect its ability to achieve the anticipated results, as well as Arrowhead’s business, results of operations and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements. Additionally, Arrowhead disclaims any intent to update these forward-looking statements to reflect subsequent developments.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Surrey reveals its implantable biosensor that operates without batteries May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Investments/IPO's/Splits

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

180 Degree Capital Corp. Selected to Manage $25 Million by Pension Fund May 6th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences May 1st, 2020

Nanomedicine

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Twisting 2D materials uncovers their superpowers: Researchers have developed a completely new method for twisting atomically thin materials, paving the way for applications of 'twistronics' based on tunable 2D materials May 12th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Engineers and scientists develop mobile technology for eye examinations: Novel photonic integrated technology will bring optical coherence tomography from stationary clinical use to mobile use May 7th, 2020

Announcements

An EPiQS Pursuit: Physicist Andrea Young is chosen to receive an Experimental Investigator award from the Moore Foundation May 28th, 2020

Study finds electrical fields can throw a curveball: Particle-scale phenomenon akin to the swerving of a curveball could allow selective separation of suspended nanomaterials May 26th, 2020

Visualization of functional components to characterize optimal composite electrodes May 22nd, 2020

Researchers demonstrate transport of mechanical energy, even through damaged pathways: Topological pump can provide stability for communication technologies May 22nd, 2020

Nanobiotechnology

2D sandwich sees molecules with clarity: Rice University engineers adapt 2D ‘sandwich’ for surface-enhanced Raman spectroscopy May 15th, 2020

Chemistry breakthrough could speed up drug development: Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development May 8th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences May 1st, 2020

Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given May 1st, 2020

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project